281 related articles for article (PubMed ID: 21831227)
61. Treatment of acute humoral rejection in kidney transplantation with plasmapheresis.
Grandtnerová B; Javorský P; Kolácný J; Hovoricová B; Dĕdic P; Laca L
Transplant Proc; 1995 Feb; 27(1):934-5. PubMed ID: 7879238
[No Abstract] [Full Text] [Related]
62. [Indications for apheresis in kidney transplant recipients: apheresis in the hyperimmune patient].
Busnach G; Di Leo L
G Ital Nefrol; 2012; 29 Suppl 54():S22-6. PubMed ID: 22388825
[TBL] [Abstract][Full Text] [Related]
63. Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience.
Padmanabhan A; Ratner LE; Jhang JS; Duong JK; Markowitz GS; Vasilescu ER; Crew RJ; Schwartz J
Transplantation; 2009 Jun; 87(12):1889-96. PubMed ID: 19543070
[TBL] [Abstract][Full Text] [Related]
64. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
65. [Antibody-mediated acute rejection].
Lefaucheur C; Nochy D; Glotz D
Nephrol Ther; 2008 Oct; 4 Suppl 3():S188-91. PubMed ID: 19000885
[TBL] [Abstract][Full Text] [Related]
66. Progress in understanding humoral rejection in kidney transplantation: implications for patient management.
Pascual MA; Crespo M; Tolkoff-Rubin N
Nefrologia; 2001; 21(4):327-31. PubMed ID: 11816504
[TBL] [Abstract][Full Text] [Related]
67. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
68. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation.
Lehrich RW; Rocha PN; Reinsmoen N; Greenberg A; Butterly DW; Howell DN; Smith SR
Hum Immunol; 2005 Apr; 66(4):350-8. PubMed ID: 15866697
[TBL] [Abstract][Full Text] [Related]
69. A refractory case of subclinical antibody-mediated rejection due to anti-HLA-DQ antibody in a kidney transplant patient.
Fujimoto T; Nakada Y; Yamamoto I; Kobayashi A; Tanno Y; Yamada H; Miki J; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():81-5. PubMed ID: 26031594
[TBL] [Abstract][Full Text] [Related]
70. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation.
Gloor JM; DeGoey S; Ploeger N; Gebel H; Bray R; Moore SB; Dean PG; Stegall MD
Transplantation; 2004 Jul; 78(2):221-7. PubMed ID: 15280682
[TBL] [Abstract][Full Text] [Related]
71. Therapeutic apheresis in kidney transplantation: a review of renal transplant immunobiology and current interventions with apheresis medicine.
Nishio-Lucar A; Balogun RA; Sanoff S
J Clin Apher; 2013 Feb; 28(1):56-63. PubMed ID: 23420595
[TBL] [Abstract][Full Text] [Related]
72. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation.
Bartel G; Wahrmann M; Regele H; Kikić Z; Fischer G; Druml W; Mühlbacher F; Böhmig GA
Am J Transplant; 2010 Sep; 10(9):2033-42. PubMed ID: 20883537
[TBL] [Abstract][Full Text] [Related]
73. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
[TBL] [Abstract][Full Text] [Related]
74. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor.
Gupta A; Sinnott P
Hum Immunol; 2009 Aug; 70(8):618-22. PubMed ID: 19374932
[TBL] [Abstract][Full Text] [Related]
75. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
[TBL] [Abstract][Full Text] [Related]
76. Post-transplant Desensitization for Deceased Donor Kidney Transplant Recipients: A Single Center Experience.
Kumar D; Fattah H; Kimball PM; LeCorchick S; McDougan FA; King AL; Gupta G
Clin Transpl; 2016; 32():143-151. PubMed ID: 28564532
[TBL] [Abstract][Full Text] [Related]
77. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients.
Akalin E; Bromberg JS
Hum Immunol; 2005 Apr; 66(4):359-63. PubMed ID: 15866698
[TBL] [Abstract][Full Text] [Related]
78. Desensitization: achieving immune detente.
Zachary AA; Eng HS
Tissue Antigens; 2011 Jan; 77(1):3-8. PubMed ID: 21155718
[TBL] [Abstract][Full Text] [Related]
79. Desensitization and crossmatch conversion in deceased donor kidney transplantation.
Bartel G; Böhmig GA
Minerva Urol Nefrol; 2011 Mar; 63(1):21-34. PubMed ID: 21336243
[TBL] [Abstract][Full Text] [Related]
80. Immunoadsorption with protein A in humoral acute rejection of kidney transplants: multicenter experience.
Mastrangelo F; Pretagostini R; Berloco P; Poli L; Cinti P; Patruno P; Alfonso L; Pompei L; Carboni F; Rizzelli S
Transplant Proc; 1995 Feb; 27(1):892-5. PubMed ID: 7879221
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
